Trial Profile
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Dendritic cell vaccines (Primary) ; Fludarabine (Primary) ; Mipetresgene autoleucel (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Aug 2019 Status changed from recruiting to completed.
- 12 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.